Introduction
One of the primary aims of endoscopic sinus surgery (ESS) is to enlarge the sinus ostia to facilitate sinus drainage and aeration and thereby prevent future sinus infections. However, lateral synechia formation between the middle turbinate and the lateral nasal wall is Several factors contribute to lateralization of the middle turbinate with or without synechia formation: (1) trauma to the lateral mucosal surface of the middle turbinate, (2) resection of the horizontal portion of the basal lamella, (3) improper manipulation of the middle turbinate resulting in a floppy turbinate, (4) severe polyposis surrounding the middle turbinate, (5) postoperative swelling, (6) inadequate postoperative debridement, and (7) improper packing of the nasal airway after surgery. 3 Scar tissue formation (1) can lead to outflow tract obstruction from the ethmoid, frontal, and maxillary cavities, (2) prevents adequate sinus debridement after surgery, (3) results in poor drainage and aeration, and (4) possibly leads to the need for revision surgery.
In 1999, Bolger et al published a short communication entitled, "A Targeted Problem and Its Solution," in which they described their technique for creating a controlled synechia between the middle turbinate and the nasal septum to prevent lateralization of the middle turbinate. 3 Since then, many modifications have been described to address the issue of middle turbinate lateralization and synechia formation with the lateral wall. [4] [5] [6] [7] [8] [9] [10] [11] These include partial turbinectomy, middle turbinate suture conchopexy, and the placement of septal flaps, metal clips, bioabsorbable implants, and middle meatal spacers.
In this article, we describe our experience with the middle turbinate medialization technique described by Bolger et al 3 on a cohort of patients undergoing ESS, and we compare our findings with those of a control group.
Patients and methods
Patients. Our study population was made up of 142 adults-70 men and 72 women (mean age: 52.3 yr)-who had not responded to medical therapy for chronic rhinosinusitis and who had subsequently undergone ESS (table 1) . Chronic rhinosinusitis was defined as a symptomatic inflammation of the sinuses for at least 3 months. Patients with previous ESS, a concha bullosa,
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OVERDOSAGE
Due to the characteristics of this preparation, no toxic effects are to be expected with an otic overdose of OTOVEL. environmental allergies, asthma, and aspirin intolerance were included in the study. We did not include any patients who were younger than 18 years, who were lost to follow-up, and who had simultaneous inferior turbinate surgery, septoplasty, or other nasal surgery. The diagnosis of chronic rhinosinusitis, the presence of unilateral or bilateral sinusitis, and the indications for surgery were confirmed by computed tomography and endoscopic examination in all patients. The most common symptoms were nasal congestion (91% of cases), headache (53%), postnasal drip (35%), nasal discharge (32%), and olfactory disturbance (8%).
Before December 2013, surgeons at our institution did not perform medialization turbinoplasty consistently. Of the 142 patients in this study, 52 had undergone ESS from July through December 2013; none had undergone turbinoplasty. Their ESS records were reviewed retrospectively, and these patients served as our control group. Of the 52 controls, 38 underwent a bilateral procedure and 14 a unilateral procedure, for a total of 90 operated sides.
Our turbinoplasty group originally included 94 patients. They were operated on from January though December 2014. Their ESS was performed bilaterally in 70 patients and unilaterally in 24 patients, for a total of 164 sides. Four of the 94 patients were lost to follow-up, leaving us with a cohort of 90 patients (156 sides). In addition, turbinoplasty was not performed in another 11 sides because the turbinate was partially or completely absent as a result of previous surgery or other causes such as excessive scarring where it was deemed necessary to resect the middle turbinate. This resulted in a total of 145 turbinoplasty sides.
Surgical technique. At our hospital, ESS begins with packing of the involved side of the nose and middle meatus with oxymetazoline packs for a few minutes. The packs are then removed, and lidocaine 1% with epinephrine 1:200,000 is injected into the uncinate process and root of the middle turbinate. In some cases, injection of epinephrine is not performed-for example, when a patient is hypertensive and/or older than 70 years or when the anesthesiologist requests that it not be done.
Before the initiation of the actual sinus surgery, a small upbiting Thrubite forceps is used to remove 2 to 3 mm of mucosa from the medial surface of the middle turbinate and the adjacent nasal septum (figure 1). Sinus packs are then placed lateral to the middle turbinate. If a microdebrider is used, then the mucosal surfaces are denuded in the same location with the blade of the microdebrider. The middle turbinate is immediately pushed medially with a Freer elevator, which allows the raw surfaces to come into contact with each other; the elevator is held in position for 5 to 10 seconds.
During the remainder of the procedure, we try not to manipulate the middle turbinate but to keep it medialized. When a concha bullosa is present, its medial portion is resected along with the opposing 3 mm of the nasal septal mucosa. During the rest of the procedure, we try to keep the middle turbinate medialized.
The uncinate process is then identified and medialized with a Cottle elevator, and an uncinectomy is performed with a straight Thrubite forceps. The surgery is then performed, and the sinuses are opened as indicated by the patient's disease. In general, middle turbinate medialization takes only a few seconds. It is typically performed at the beginning of the procedure, but it can be performed at any time during surgery.
At the conclusion of the ESS, Merocel packs are inserted in the middle meatus and allowed to expand via irrigation, thus maintaining the middle turbinate in a medialized position and allowing it to come into contact with the nasal septum. The packs are removed in the office 4 to 5 days later. Patients are administered an antibiotic while the packs are in place.
Postoperative outcomes and measures. Our primary outcomes measures were the postoperative endoscopic position of the middle turbinate and the presence or absence of lateral synechia formation. Postoperative endoscopic examinations were performed on all patients. Postoperative visits and endoscopic examinations were done at 5 days, 2 weeks, 3 weeks, 3 months, and 6 months after ESS. Both groups were followed for 6 to 12 months. At each postoperative visit, patients were assessed for middle turbinate positioning, synechia formation, the ease of debriding the sinus cavities, and recurrence of symptoms. The position of the middle turbinate was classified as either medial (touching the nasal septum), neutral (midway between the septum and lateral wall), or lateral (touching the lateral wall or preventing adequate visualization of the middle meatus). Symptoms or the lack thereof, including any changes in sense of smell, were recorded.
Ethical considerations. The study protocol was approved by the Institutional Review Board of the Tufts University School of Medicine.
Results
Of the 146 patients in the entire study before the loss of the 4 patients to follow-up, 114 (78%) reported significant improvement after surgery and 21 (14%) reported some improvement.
In the final study population, the position of the middle turbinate was satisfactory (i.e., in the medial or neutral position) on 210 sides (89%) and relateralized on 25 (11%). In 9 of those 25 sides, the middle turbinate lateralized without an obstruction of the middle meatus or a recurrence of symptoms; in the other 16 cases, the middle turbinate lateralized and did cause obstruction or opacification of the middle meatus, and these cases warranted a partial or complete revision turbinectomy, depending on the severity of the scarring.
At the 3-month follow-up, the rate of middle turbinate medialization was significantly higher in the turbinoplasty group than in the nonturbinoplasty group-68 vs. 19% (p < 0.001) (table 2). In the turbinoplasty group, 99 sides demonstrated middle turbinate medialization that featured a well-defined synechia between the septum and the middle turbinate (figure 2).
The rate of lateral displacement with synechia formation was just slightly higher in nonturbinoplasty group-13 vs. 9% (p = 0.29) (table 2). Complications were observed in 5 patients. They included postoperative bleeding in 3, a cerebrospinal fluid (CSF) leak in 1, and periorbital ecchymosis in 1. The bleeding was controlled with packing in 2 patients and with surgical cautery of the septal branch of the sphenopalatine artery in the other. The CSF leak was repaired immediately with a septal flap. The patient with periorbital ecchymosis did not exhibit any ocular findings or visual changes. None of the complications was attributable to middle turbinate medialization. There were no cases of vision loss, diplopia, or orbital hematoma. We also found that sense of smell was not adversely altered after middle turbinate medialization, a finding that was previously reported by Dutton and Hinton. 12 
Discussion
Many surgical techniques have been described that address the issue of middle turbinate lateralization and synechia formation with the lateral wall. No consensus has been reached on a single standard procedure because the various techniques all have their benefits and disadvantages.
LaMear et al advocated partial resection of the middle turbinate. 13 However, that can still result in synechia formation and lateralization of the superior portion of the turbinate. Furthermore, the middle turbinate serves as an important anatomic landmark and is believed to improve nasal humidification, so we prefer to preserve it when possible. Thornton's technique of suture conchopexy has had a high success rate in preventing middle turbinate lateralization. 10 However, this Creating a synechia by denuding the medial aspect of the middle turbinate and the nasal septum is a safe, quick, simple, and effective means of preventing lateralization. Placing nonabsorbable packing lateral to the middle turbinate for 3 or 4 days can effectively stabilize the middle turbinate. It can also prevent a "floppy" turbinate, and it is well tolerated by patients.
It is important to point out that a patent sinus cavity and a lack of synechiae do not always correlate with control of symptoms. Conversely, a well-lateralized middle turbinate and a patent meatus do not always ensure a favorable outcome. In 2015, Chen et al 2 described their comparison of postoperative endoscopic findings and Lund-Mackay scores 14 between a middle turbinate suture group and a control group; they found no statistically significant difference between the two groups. This is possibly because many other factors play a role in controlling symptoms and preventing further sinus infections. These factors include an incomplete surgery, patient compliance, proper postoperative cleaning of the sinus cavities, and control of environmental, food, and aspirin allergies in addition to many other factors.
In 1999, Ramadan found that the most common cause of treatment failure was the presence of residual air cells and adhesions in the ethmoid sinus area (30.7% of failures). 15 Other causes included maxillary sinus ostium stenosis (27%), frontal sinus ostium stenosis (25%), and a middle meatal antrostomy separate from the natural ostium with recirculation phenomena (15%).
The technique we describe provides for adequate medial positioning of the middle turbinate. Further studies need to be completed to better assess the correlation between (1) middle turbinate lateralization and the recurrence of symptoms and (2) the need for revision ESS. However, we found that medialization of the middle turbinate allowed for easy debridement and good visualization of the maxillary, ethmoid, sphenoid, and frontal sinus meatus postoperatively. This technique also provides good access for obtaining postoperative cultures if needed. We also found no correlation between middle turbinate medialization and olfactory disturbance.
In conclusion, synechia formation after ESS is a common complication that can lead to lateralization of the middle turbinate and obstruction of the middle meatus. This results in difficulty visualizing and properly debriding the sinus cavities postoperatively, which can possibly result in recurrent disease.
Medialization turbinoplasty is a simple and effective technique that is an effective solution to a problem many sinus surgeons face. It is safe, quick, and easy to perform, and it does not add to the cost or morbidity of the surgery. It provides adequate access to the ethmoid sinuses postoperatively for debridement, and it reduces the risk of middle meatal narrowing.
In our study, medialization of the middle turbinate performed in patients undergoing ESS resulted in a significantly higher rate of medialization and wide access to the middle meatus in patients who underwent turbinoplasty. We observed no complications associated with the procedure. We conclude that medialization middle turbinoplasty is effective in providing wide access after ESS while reducing the risk of middle meatal stricture.
